Journal Mobile Options
Table of Contents
Vol. 25, No. 6, 2008
Issue release date: July 2008
Dement Geriatr Cogn Disord 2008;25:539–543
(DOI:10.1159/000134382)

Higher Serum Vitamin D3 Levels Are Associated with Better Cognitive Test Performance in Patients with Alzheimer’s Disease

Oudshoorn C. · Mattace-Raso F.U.S. · van der Velde N. · Colin E.M. · van der Cammen T.J.M.
aDepartment of Internal Medicine, Section of Geriatric Medicine, and bDepartment of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Recent studies suggest that vitamin D metabolites may be important for preserving cognitive function via specific neuroprotective effects. No large studies have examined the association between vitamin D status and cognition. Methods: In this cross-sectional study, we analyzed the serum 25-hydroxyvitamin D3 levels and Mini-Mental State Examination (MMSE) test scores of 225 older outpatients who were diagnosed as having probable Alzheimer’s disease (AD). In addition to the 25-hydroxyvitamin D3 levels, we analyzed the serum vitamin B1, B6 and B12 levels. Results: An association was found between MMSE test scores and serum 25-hydroxyvitamin D3 levels, with a β-coefficient of 0.05 (p = 0.01). Vitamin-D-sufficient patients had significantly higher MMSE scores as compared to vitamin-D-insufficient ones. No association was found with the other serum vitamin levels. Conclusions: These data support the idea that a relationship exists between vitamin D status and cognition in patients with probable AD. However, given the cross-sectional design of this study, no causality can be concluded. Further prospective studies are needed to specify the contribution of vitamin D status to the onset and course of cognitive decline and AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lechowski L, de Stampa M, Denis B, Tortrat D, Chassagne P, Robert P, Teillet L, Vellas B: Patterns of loss of abilities in instrumental activities of daily living in Alzheimer’s disease: the REAL cohort study. Dement Geriatr Cogn Disord 2008;25:46–53.
  2. Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD: The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci 2002;57:M470–M472.
  3. Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ: Prevalence and impact of medical comorbidity in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2002;57:M173–M177.
  4. Whitehouse PJ: Pharmacoeconomics of dementia. Alzheimer Dis Assoc Disord 1997;11(suppl 5):S22–S32; discussion S32–S33.

    External Resources

  5. Van der Cammen TJ, Simpson JM, Fraser RM, Preker AS, Exton-Smith AN: The memory clinic: a new approach to the detection of dementia. Br J Psychiatry 1987;150:359–364.
  6. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC: Practice parameter: diagnosis of dementia (an evidence-based review) – Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–1153.
  7. CBO, Dutch Institute for Health Care Improvement: Guideline for the diagnosis and treatment of dementia (Richtlijn diagnostiek en behandeling van dementie). Alphen aan de Rijn, Van Zuiden Communications B.V., 2005.
  8. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D: New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100–105.
  9. Lips P: Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4–8.
  10. Bischoff-Ferrari HA: The 25-hydroxyvitamin D threshold for better health. J Steroid Biochem Mol Biol 2007;103:614–619.
  11. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ: Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat 2005;29:21–30.
  12. Przybelski RJ, Binkley NC: Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys 2007;460:202–205.
  13. Epstein AM, Hall JA, Besdine R, Cumella E Jr, Feldstein M, McNeil BJ, Rowe JW: The emergence of geriatric assessment units: the ‘new technology of geriatrics’. Ann Intern Med 1987;106:299–303.
  14. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  15. Van der Cammen TJ, Verschoor CJ, van Loon CP, van Harskamp F, de Koning I, Schudel WJ, Slooter AJ, Van Broeckhoven C, van Duijn CM: Risk of left ventricular dysfunction in patients with probable Alzheimer’s disease with APOE*4 allele. J Am Geriatr Soc 1998;46:962–967.
  16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM IV). Washington, American Psychiatric Association, 1994.
  17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  18. SIVIS Annual Report 1986 (SIVIS Jaarboek 1986). Utrecht, SIG/informatiecentrum voor de gezondheidszorg, 1987.
  19. Semba RD, Garrett E, Johnson BA, Guralnik JM, Fried LP: Vitamin D deficiency among older women with and without disability. Am J Clin Nutr 2000;72:1529–1534.
  20. Lips P: Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004;89–90:611–614.
  21. Lips P: Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477–501.
  22. Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266–281.
  23. Sonnenberg J, Luine VN, Krey LC, Christakos S: 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986;118:1433–1439.
  24. Van Etten E, Mathieu C: Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93–101.
  25. Morley JE, Thomas DR, Wilson MM: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–743.
  26. Suominen M, Muurinen S, Routasalo P, Soini H, Suur-Uski I, Peiponen A, Finne-Soveri H, Pitkala KH: Malnutrition and associated factors among aged residents in all nursing homes in Helsinki. Eur J Clin Nutr 2005;59:578–583.
  27. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH: Neuropsychiatric syndromes in dementia: – results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 2007;24:457–463.
  28. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR: Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res 1992;13:239–250.
  29. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W: Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004;19:265–269.
  30. Burne TH, McGrath JJ, Eyles DW, Mackay-Sim A: Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res 2005;157:299–308.
  31. Hathcock JN, Shao A, Vieth R, Heaney R: Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6–18.
  32. Crinelli RM, Ostberg P: Folstein’s Mini-Mental State Examination: fat chance or slim hope? J Am Geriatr Soc 2008;56:171–172.
  33. Clarfield AM: The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 2003;163:2219–2229.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50